Evaluation of the effectiveness of a joint general practitioner-pharmacist intervention on the implementation of benzodiazepine deprescribing in older adults (BESTOPH-MG trial): protocol for a cluster-randomized controlled trial.

Jean-François Huon, Pierre Nizet, Pascal Caillet, Hélène Lecompte, Caroline Victorri-Vigneau, Jean-Pascal Fournier, BESTOPH-MG consortium
Author Information
  1. Jean-François Huon: Nantes Université, Univ Tours, CHU Nantes, CHU Tours, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, Nantes, France.
  2. Pierre Nizet: Nantes Université, Univ Tours, CHU Nantes, CHU Tours, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, Nantes, France.
  3. Pascal Caillet: Public Health Department, Nantes Université, CHU Nantes, Nantes, France.
  4. Hélène Lecompte: Nantes Université, Univ Tours, CHU Nantes, CHU Tours, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, Nantes, France.
  5. Caroline Victorri-Vigneau: Nantes Université, Univ Tours, CHU Nantes, CHU Tours, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, Nantes, France.
  6. Jean-Pascal Fournier: Nantes Université, Univ Tours, CHU Nantes, CHU Tours, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, Nantes, France.

Abstract

Background: Deprescribing benzodiazepines and related drugs (BZDR) is a challenge due to a lack of time on physicians' part, a lack of involvement of other health professionals, and the need for adapted tools. This study is based on primary care collaboration, by evaluating the effectiveness of a joint intervention between general practitioners and community pharmacists on the implementation of BZDR deprescribing in older adults.
Methods: This is a cluster randomized controlled trial in which each cluster will be formed by a physician-pharmacist pair. Within a cluster allocated to the intervention, the pharmacist will be trained in motivational interviewing (MI), and will offer the patient 3 interviews after inclusion by the physician. They will base their intervention on validated deprescribing guidelines. The pharmacist will receive methodological support during the first interviews. Interprofessional collaboration will be encouraged by writing reports for the physician after each interview. The following implementation outcomes will be evaluated: acceptability/adoption, appropriateness, cost, and fidelity. They will be measured by means of sociological interviews, observations, logbooks, and cost-utility analysis. Focus groups with physicians and pharmacists will be carried out to identify levers and barriers experienced in this collaboration. Observations will be conducted with pharmacists to assess their approach of the MIs. Effectiveness outcomes will be based on medication (discontinuation or reduction of BZDR) and clinical outcomes (such as quality of life, insomnia or anxiety), assessed by health insurance databases and validated questionnaires.
Discussion: This study will determine whether collaboration in primary care between physicians and pharmacists, as well as training and coaching of pharmacists in motivational interviewing, allows the implementation of BZDR deprescribing in the older adults.This study will provide an understanding of the processes used to implement deprescribing guidelines, and the contribution of collaborative practice in implementing BZDR discontinuation. The cluster methodology will allow to assess the experience of the relationship between the different primary care actors, and the related obstacles and levers.The results obtained will make it possible to produce guidelines on the involvement of community pharmacists in the management of substance abuse in older adults, or even to legislate new missions or care pathways.
Clinical trial registration: ClinicalTrials.gov, identifier, NCT05765656.

Keywords

Associated Data

ClinicalTrials.gov | NCT05765656

References

  1. Drugs Aging. 2022 Sep;39(9):739-748 [PMID: 35896779]
  2. Syst Rev. 2022 Aug 13;11(1):169 [PMID: 35964148]
  3. J Clin Psychopharmacol. 2000 Feb;20(1):99 [PMID: 10653216]
  4. J Pers Med. 2022 Apr 15;12(4): [PMID: 35455759]
  5. BMC Med Res Methodol. 2003 Dec 22;3:28 [PMID: 14690550]
  6. Curr Opin Psychiatry. 2005 May;18(3):249-55 [PMID: 16639148]
  7. Trials. 2014 Apr 23;15:139 [PMID: 24755011]
  8. Patient Educ Couns. 2004 May;53(2):147-55 [PMID: 15140454]
  9. Int J Environ Res Public Health. 2023 Feb 17;20(4): [PMID: 36834238]
  10. Drug Saf. 2021 Jan;44(1):53-62 [PMID: 33125663]
  11. Implement Sci. 2022 Jul 8;17(1):41 [PMID: 35804428]
  12. BMC Geriatr. 2023 Jul 12;23(1):428 [PMID: 37438697]
  13. BMJ. 2005 Nov 19;331(7526):1169 [PMID: 16284208]
  14. Ann Pharm Fr. 2012 Jan;70(1):46-52 [PMID: 22341008]
  15. BMJ Open. 2019 Jan 30;9(1):e022046 [PMID: 30705235]
  16. Curr Psychiatry Rep. 2016 Oct;18(10):89 [PMID: 27549604]
  17. Pharmacol Res Perspect. 2019 Apr 25;7(3):e00476 [PMID: 31049205]
  18. J Am Geriatr Soc. 1999 Jan;47(1):30-9 [PMID: 9920227]
  19. Patient Educ Couns. 2022 Mar;105(3):615-624 [PMID: 34183219]
  20. Br J Clin Pharmacol. 2021 Mar;87(3):722-724 [PMID: 32851681]
  21. J Pain. 2017 Mar;18(3):308-318 [PMID: 27908840]
  22. Contemp Clin Trials. 2005 Apr;26(2):260-7 [PMID: 15837446]
  23. Presse Med. 2018 Oct;47(10):878-881 [PMID: 30454579]
  24. JAMA. 2018 Nov 13;320(18):1889-1898 [PMID: 30422193]
  25. Fam Pract. 1994 Dec;11(4):358-62 [PMID: 7895961]
  26. Int J Epidemiol. 2020 Jun 1;49(3):979-995 [PMID: 32087011]
  27. JAMA Intern Med. 2014 Jun;174(6):890-8 [PMID: 24733354]
  28. BMJ. 2014 Sep 09;349:g5205 [PMID: 25208536]
  29. JAMA Intern Med. 2015 May;175(5):827-34 [PMID: 25798731]
  30. Ther Adv Drug Saf. 2022 Aug 23;13:20420986221118143 [PMID: 36052398]
  31. Can Fam Physician. 2018 Aug;64(8):584-587 [PMID: 30108077]
  32. Pharmacoeconomics. 2006;24(7):683-94 [PMID: 16802844]
  33. Adm Policy Ment Health. 2011 Mar;38(2):65-76 [PMID: 20957426]
  34. Eur J Intern Med. 2017 Mar;38:3-11 [PMID: 28063660]
  35. Res Social Adm Pharm. 2018 Jan;14(1):18-25 [PMID: 28214150]
  36. PLoS One. 2016 Apr 19;11(4):e0151066 [PMID: 27093289]
  37. JAMA. 2013 Jun 12;309(22):2331-2 [PMID: 23700165]
  38. J Gerontol A Biol Sci Med Sci. 2007 Oct;62(10):1172-81 [PMID: 17921433]
  39. Psychol Med. 2003 Oct;33(7):1223-37 [PMID: 14580077]
  40. Health Expect. 2022 Feb;25(1):355-365 [PMID: 34862703]
  41. Drugs Aging. 2022 Oct;39(10):773-794 [PMID: 36194370]
  42. EClinicalMedicine. 2020 Oct 16;28:100596 [PMID: 33294812]
  43. Addict Behav. 2004 Aug;29(6):1059-65 [PMID: 15236807]
  44. Cochrane Database Syst Rev. 2011 May 11;(5):CD008063 [PMID: 21563163]
  45. N Engl J Med. 2016 Aug 4;375(5):454-63 [PMID: 27518663]

Word Cloud

Created with Highcharts 10.0.0willpharmacistsdeprescribingBZDRcareimplementationprimarycollaborationinterventionolderadultsclustertrialstudyinterviewsguidelinesoutcomesbenzodiazepinesrelatedlackinvolvementhealthbasedeffectivenessjointgeneralcommunitycontrolledpharmacistmotivationalinterviewingphysicianvalidatedphysiciansleversassessdiscontinuationcollaborativepracticeBackground:Deprescribingdrugschallengeduetimephysicians'partprofessionalsneedadaptedtoolsevaluatingpractitionersMethods:randomizedformedphysician-pharmacistpairWithinallocatedtrainedMIofferpatient3inclusionbasereceivemethodologicalsupportfirstInterprofessionalencouragedwritingreportsinterviewfollowingevaluated:acceptability/adoptionappropriatenesscostfidelitymeasuredmeanssociologicalobservationslogbookscost-utilityanalysisFocusgroupscarriedidentifybarriersexperiencedObservationsconductedapproachMIsEffectivenessmedicationreductionclinicalqualitylifeinsomniaanxietyassessedinsurancedatabasesquestionnairesDiscussion:determinewhetherwelltrainingcoachingallowsThisprovideunderstandingprocessesusedimplementcontributionimplementingmethodologyallowexperiencerelationshipdifferentactorsobstaclesTheresultsobtainedmakepossibleproducemanagementsubstanceabuseevenlegislatenewmissionspathwaysClinicalregistration:ClinicalTrialsgovidentifierNCT05765656Evaluationpractitioner-pharmacistbenzodiazepineBESTOPH-MG:protocolcluster-randomized

Similar Articles

Cited By